jens juul holst glp-1 The Story of Jens Juul Holst - Gairdner

The peptide world has been racing toward dual and triple agonism (e.g

The Bests Company Report(s) reproduced on this site appear under license from A.M

23

In spite of the rising adoption, a recent report revealed 60 percent stopped using their GLP-1 medication before reaching their targeted duration, with many citing negative side effects as a factor for quitting the medication

Achievement of HbA1c 6.5% : Over 65% of participants on the 36 mg dose reached this target, meeting the defined threshold for glycemic control

While they use the same active ingredient, equivalence to FDA-approved finished products should not be assumed